洁瑞品牌怎么样 申请店铺

我要投票 洁瑞在医疗器械行业中的票数:185 更新时间:2025-04-04
洁瑞是哪个国家的品牌?「洁瑞」是 山东威高集团医用高分子制品股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人张华威在2000-12-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力洁瑞品牌出海!通过在本页面挂载洁瑞品牌的产品链接和联系邮箱,可以提高洁瑞产品曝光!跨境电商爆单神器,目前只要100元/年哦~

洁瑞怎么样

山东威高集团医用高分子制品股份有限公司(「本公司」)及其附属公司(「本集团」)主要从事研发、生产及销售医用耗材、骨科材料、心脏支架等。本公司为国家高技术研究发展(863)计划成果产业化基地、国家级高新技术企业。本集团主要生产基地位于山东省威海市。

本集团在中国注册,拥有一个由18个销售办事处及21个客户联络中心和107多家城市代表处组成的庞大销售网络,并已建立广泛的客户基础,其产品销售予5,400多家医疗单位和分销商,其中包括医院2800多家、血站400多家、其它医疗单位700多家和逾1,500家贸易公司。

本集团生产的产品种类多达150余种,产品规格超过5000种,产品可分为六大系列,即1)一次性使用医疗耗材及原料,其中包括输液(血)器、注射器、血袋与血液成份分离耗材、采血系列耗材、齿科耗材和麻醉系列耗材等,以及医用PVC粒料和非PVC粒料等;2)骨科材料及工具,主要包括钢板、螺钉等创伤治疗耗材、脊柱系列耗材及正在发展的人工关节系列耗材;3)医用针制品,主要包括静脉针、注射针、留置针、采血针、异形针等系列制品;4)血液净化系列耗材,主要包括穿刺针、血液回路管、透析器等肾科耗材,以及用于红斑狼疮、器官移植排异反应、类风湿关节炎等免疫系统疾病治疗的免疫吸附柱,以及其它正在研发和注册的LDL吸附柱、内毒素吸附柱和乙肝病毒吸附柱等;5)心脏支架产品,主要包括药物涂层心脏支架、球囊等;6)用于药品包装的预充式注射器。

“国家高技术研究发展(863)计划成果产业化基地”、“国家级企业技术中心”,并建有企业博士后工作站。公司积极开展产、学、研合作,与中科院长春应用化学研究所、中科院大连化学物理研究所、中科院沈阳金属研究所、第三军医大学、301医院、哈工大(威海)等科研院所、院校紧密合作,并聘请了10位两院院士做顾问,依托其人才和科研力量,异地建立了九个威高集团研发中心,立足行业制高点,消化吸收国际前沿技术,开发具有自主知识产权的高科技产品。公司有60多个产品达到国内外先进水平,不少产品填补了国内空白,20个产品入选国家863计划、国家重点火炬计划、国家高技术产业示范化工程、国家级重点新产品等国家各类项目,其中药物涂层支架系统、预充式注射器、骨科植入材料等产品打破了国外公司对中国市场的垄断。

集团注重产品品牌的长远发展,强调其产品质量。自2001年11月以来,集团的一次性使用无菌输液器、一次性使用无菌输血器及一次性使用无菌注射器的生产及服务的质量体系获中国医疗器械质量认证中心授予ISO9001:2000认证、中国CMD认证。从1999年12月,集团的输液器、输血器、一次性使用注射器及塑料血袋等产品种类获得由TÜVProductServiceGmbh颁发的CE认证证书以来,本集团已先后获得一次性使用自动取血器、一次性使用CT增强注射器造影剂针筒、一次性使用自毁式安全注射器、自动缩回式安全注射器、骨科器械、金属接骨板,脊柱内固定系统,金属接骨螺钉、带锁髓内钉、一次性使用无菌注射针、一次性使用静脉留置针、无针密闭输液接头等产品及体系的CE认证。于2003年12月5日,集团的产品质量检查中心获中国实验室国家认可委员会评为符合国家测试及定标规定。于2005年6月23日,集团拥有的商标被中国国家工商行政管理总局认定为中国国内医疗器械行业第一个中国驰名商标。

目前,集团的销售主要在中国市场,本集团正积极开拓国际市场,产品已经出口美国、德国、罗马尼亚、澳大利亚和英国等30个国家和地区。

Shandong Weigao group medical polymer products Co., Ltd. (the "company") and its subsidiaries (the "group") are mainly engaged in research and development, production and sales of medical consumables, orthopedic materials, heart stents, etc. The company is the industrialization base of national high-tech research and development (863) plan achievement and national high-tech enterprise. The main production base of the group is located in Weihai City, Shandong Province. Registered in China, the group has a huge sales network consisting of 18 sales offices, 21 customer contact centers and 107 city representative offices, and has established a wide customer base. Its products are sold to more than 5400 medical units and distributors, including more than 2800 hospitals, more than 400 blood stations, more than 700 other medical units and more than 1500 trading companies. The group produces more than 150 kinds of products with more than 5000 specifications, which can be divided into six series, i.e. 1) disposable medical consumables and raw materials, including infusion (blood) devices, syringes, blood bag and blood component separation consumables, blood collection consumables, dental consumables and anesthesia consumables, as well as medical PVC granules and non PVC granules; 2) orthopedic materials And tools, mainly including steel plate, screw and other trauma treatment consumables, spine series consumables and developing artificial joint series consumables; 3) medical needle products, mainly including vein needle, injection needle, retention needle, blood sampling needle, abnormal needle and other series products; 4) blood purification series consumables, mainly including puncture needle, blood circuit tube, dialyzer and other renal consumables, as well as for erythema Immunosorbent columns for the treatment of immune system diseases such as lupus, organ transplantation rejection, rheumatoid arthritis, and other LDL, endotoxin and hepatitis B virus adsorption columns under development and registration; 5) cardiac stent products, mainly including drug coated cardiac stent, balloon, etc.; 6) pre filled syringes for drug packaging. "National High Tech Research and development (863) plan achievement industrialization base", "national enterprise technology center", and built enterprise postdoctoral workstation. The company actively carries out cooperation in production, learning and research, closely cooperates with Changchun Institute of Applied Chemistry of Chinese Academy of Sciences, Dalian Institute of Chemical Physics of Chinese Academy of Sciences, Shenyang Institute of metals of Chinese Academy of Sciences, the Third Military Medical University, 301 Hospital, Harbin University of Technology (Weihai) and other scientific research institutes and colleges, and employs 10 academicians of the two academies as consultants. Relying on their talents and scientific research forces, the company has established nine Weiwei in different places High Tech Group R & D center, based on the industry commanding point, digests and absorbs international cutting-edge technology, and develops high-tech products with independent intellectual property rights. More than 60 products of the company have reached the advanced level at home and abroad, and many products have filled in the gaps at home. 20 products have been selected into various national projects such as the National 863 plan, the national key torch plan, the national high-tech industrial demonstration project, and the national key new products, among which drug coated stent system, pre filled syringe, orthopedic implant materials and other products have broken the foreign companies' commitment to China Market monopoly. The group pays attention to the long-term development of the product brand and emphasizes its product quality. Since November 2001, the group's quality system for the production and service of disposable sterile infusion sets, disposable sterile infusion sets and disposable sterile syringes has been awarded ISO9001:2000 certification and China CMD certification by China Medical Device Quality Certification Center. Since December 1999, the group's infusion sets, blood transfusion sets, disposable syringes and plastic blood bags have obtained CE certification issued by t Ü vproductservicegmbh, the group has successively obtained disposable automatic blood collection sets, disposable CT enhanced syringe contrast agent syringes, disposable self destructed safety syringes and automatic retracted safety syringes CE certification of orthopedic instruments, metal plates, spine internal fixation system, metal screws, interlocking intramedullary nails, disposable sterile injection needles, disposable intravenous indwelling needles, needle free closed infusion joints and other products and systems. On December 5, 2003, the group's product quality inspection center was awarded the National Accreditation Committee of China laboratories as meeting the national testing and calibration regulations. On June 23, 2005, the trademark owned by the group was recognized by the State Administration for Industry and commerce as the first well-known trademark in China's domestic medical device industry. At present, the group's sales are mainly in the Chinese market, and the group is actively exploring the international market. Its products have been exported to 30 countries and regions such as the United States, Germany, Romania, Australia and the United Kingdom.

本文链接: https://brand.waitui.com/b82feb6b3.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

英特尔和台积电达成初步协议 将成立芯片制造合资企业

两名参与谈判的人士3日表示,英特尔和台积电已达成初步协议,将成立一家合资企业来运营这家美国芯片制造商的工厂。报道称,全球最大芯片代工商台积电将持有新公司20%的股份。据悉,美国白宫和商务部官员一直在敦促台积电和英特尔达成协议,以解决英特尔的长期危机。(财联社)

2小时前

日本央行副行长内田真一:若经济改善、物价上涨,将加息

日本央行副行长内田真一表示,美国关税措施对价格影响好坏参半。在经济持续改善的背景下,如果潜在通胀加剧,将会加息。预计关税对价格既有上行影响,也有下行影响。我们将在每次会议上仔细审查经济、价格动态和风险,包括美国关税的影响,特朗普关税可能给日本和全球经济带来下行压力。(新浪财经)

2小时前

德国汽车业界:美关税政策不是“美国优先”而是“美国孤立”

当地时间2日,美国总统特朗普签署所谓“对等关税”行政令,同时自3日起,美国对所有外国制造的进口汽车加征25%关税正式生效,针对汽车零部件的关税将在5月3日前全面生效。作为全球主要的汽车制造国之一,德国的汽车产业高度依赖国际市场,而美国长期以来一直都是德国汽车企业的重要出口目的地。 德国业内人士警告,美国此举将加剧全球供应链的不确定性,并对包括德国在内的全球汽车制造商带来沉重打击。德国汽车工业协会主席希尔德加德·穆勒在3日发表的声明中批评称,美国对汽车行业加征25%的额外关税是对全球供应链的严重打击,可能对德国汽车企业及其在美投资带来不确定性。“特朗普的政策不是‘美国优先’,而是‘美国孤立’。这种保护主义做法只会带来更多输家,最终受影响的将是美国消费者、企业乃至全球经济。”(财联社)

2小时前

知情人士回应余承东卸任车BU董事长:并非不管汽车业务,更加聚焦华为终端与鸿蒙智行

华为官网和余承东的个人微博认证信息发生变更,其职位目前为“常务董事、终端BG董事长”,不再包含“智能汽车解决方案BU董事长”。 知情人士向新浪科技表示,余承东不再兼任华为车BU董事长,不是不管汽车业务,而是更加聚焦华为终端与鸿蒙智行。 鸿蒙智行以高“含华量”打造了独特的汽车生态应用场景。引望正在装载华为原车BU业务,推广解决方案,二者布局清晰、分工明确。(新浪科技)

2小时前

中信证券:关税对黄金的后续扰动可能在推高金价的同时,存在先高后低的节奏变化

北京时间4月3日凌晨,美国总统特朗普在白宫签署两项关于所谓“对等关税”的行政令。中信证券研报认为,关税对黄金的后续扰动可能在推高金价的同时,存在先高后低的节奏变化。市场面对如此多的不确定性极难形成稳定预期,因此短期内黄金市场可能有较大波动。(证券时报)

2小时前

本页详细列出关于仁和可立克的品牌信息,含品牌所属公司介绍,仁和可立克所处行业的品牌地位及优势。
咨询